


PHARMACEUTICAL 2021



ENANTA PHARMACEUTICALS INC Rank 18 of 402







RealRate





ENANTA PHARMACEUTICALS INC Rank 18 of 402

The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 242% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	436,837
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,157
Liabilities, Non-Current	4,916
Other Assets	40,699
Other Compr. Net Income	698
Other Expenses	1,149
Other Liabilities	1,479
Other Net Income	6,620
Other Revenues	122,473
Property and Equipment	8,596
Research and Development	136,756
Selling, General and Administrative Expense	27,356

Output Variable	Value in 1000 USD
Assets	486,132
Liabilities	30,552
Expenses	165,261
Revenues	122,473
Stockholders Equity	455,580
Net Income	-36,168
Comprehensive Net Income	-35,819
Economic Capital Ratio	289%

